[Thyrotropin-secreting pituitary adenomas].
TSH-secreting pituitary adenomas represent 0.5 to 1% of all pituitary adenomas. They are recognized with increasing frequency due to the measurement of TSH level in patients with hyperthyroidism, the ultra sensitive TSH assays and the improvement in pituitary imaging. Patients present mild or moderate signs of hyperthyroidism. Hormonal evaluation shows increased free thyroid hormone concentration with detectable, normal or increased serum TSH level, raising the differential diagnosis with pituitary resistance to thyroid hormone syndrome. Magnetic resonance imaging reveals pituitary adenomas in most patients. Transphenoidal surgery remains the treatment of choice in patients with TSH-secreting pituitary microadenomas, while long-acting somatostatin analogs seem to be an alternative medical treatment to surgery in patients with macroadenomas or invasive pituitary tumors.
Caron
Philippe
P
Service d'endocrinologie, maladies métaboliques et nutrition, Pôle cardiovasculaire et métabolique, CHU Larrey, F-31059 Toulouse Cedex 9, France. caron.p@chu-toulouse.fr
D000236:Adenoma / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery; D003937:Diagnosis, Differential; D006801:Humans; D006980:Hyperthyroidism / Q000175:diagnosis; D008279:Magnetic Resonance Imaging; D020360:Neoadjuvant Therapy; D010911:Pituitary Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013972:Thyrotropin / Q000097:blood / Q000378:metabolism*; D013974:Thyroxine / Q000097:blood
D013004:Somatostatin; D013972:Thyrotropin; D013974:Thyroxine